CN110087662A - 用溶瘤病毒表达pten-long - Google Patents

用溶瘤病毒表达pten-long Download PDF

Info

Publication number
CN110087662A
CN110087662A CN201780059869.5A CN201780059869A CN110087662A CN 110087662 A CN110087662 A CN 110087662A CN 201780059869 A CN201780059869 A CN 201780059869A CN 110087662 A CN110087662 A CN 110087662A
Authority
CN
China
Prior art keywords
cells
virus
pten
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780059869.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·考尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CN110087662A publication Critical patent/CN110087662A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201780059869.5A 2016-07-29 2017-07-31 用溶瘤病毒表达pten-long Pending CN110087662A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368822P 2016-07-29 2016-07-29
US62/368,822 2016-07-29
US201762479671P 2017-03-31 2017-03-31
US62/479,671 2017-03-31
PCT/US2017/044683 WO2018023114A1 (en) 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses

Publications (1)

Publication Number Publication Date
CN110087662A true CN110087662A (zh) 2019-08-02

Family

ID=61016870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780059869.5A Pending CN110087662A (zh) 2016-07-29 2017-07-31 用溶瘤病毒表达pten-long

Country Status (8)

Country Link
US (2) US20200085890A1 (https=)
EP (2) EP3490574B8 (https=)
JP (3) JP7638061B2 (https=)
KR (1) KR102780496B1 (https=)
CN (1) CN110087662A (https=)
AU (1) AU2017301901B2 (https=)
SG (1) SG11201900815UA (https=)
WO (1) WO2018023114A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2019032866A1 (en) * 2017-08-09 2019-02-14 Ohio State Innovation Foundation ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CN108484780A (zh) * 2018-04-16 2018-09-04 河南大学 一种融合蛋白PTEN-L-p53及其应用
US20220169997A1 (en) * 2019-04-12 2022-06-02 Therapten Biosciences Inc. Compositions and methods to manufacture tumor suppressor fusions
AU2020325825B2 (en) * 2019-08-05 2026-02-05 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
CN111763260B (zh) * 2020-06-11 2022-03-29 四川大学华西医院 一种PTEN-Long多克隆抗体及其制备方法和用途
WO2024163335A2 (en) * 2023-01-30 2024-08-08 The Board Of Regents Of The University Of Texas System Pten gene therapy vectors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844043A (zh) * 2010-02-17 2012-12-26 纽约哥伦比亚大学理事会 使用PTEN-Long前导序列进行分子的跨膜递送
US20140065694A1 (en) * 2011-03-03 2014-03-06 Paul-Ehrlich-Institute of the Federal Republic of Germany Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (https=) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20080292592A1 (en) * 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
WO2006096815A2 (en) * 2005-03-09 2006-09-14 Board Of Regents, The University Of Texas System NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
MX2011008695A (es) * 2009-02-17 2011-10-14 Univ Columbia Identificacion de forma extracelular del peptido largo del homologo de tensina que se puede usar para tratar tumores.
US9018182B2 (en) * 2010-04-26 2015-04-28 Green Cross Corporation Tumor specific promoter and oncolytic virus vector comprising the same
WO2013169388A1 (en) * 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy
MY177482A (en) * 2013-03-13 2020-09-16 Zhong Li Microvesicle and method for producing the same
BR112016009465A8 (pt) * 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
GB201408297D0 (en) * 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844043A (zh) * 2010-02-17 2012-12-26 纽约哥伦比亚大学理事会 使用PTEN-Long前导序列进行分子的跨膜递送
US20140065694A1 (en) * 2011-03-03 2014-03-06 Paul-Ehrlich-Institute of the Federal Republic of Germany Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENJAMIN D. HOPKINS等: "A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival", 《SCIENCE》 *
ELIZABETH A. MITTENDORF等: "PD-L1 Expression in Triple-Negative Breast Cancer", 《CANCER IMMUNOLOGY RESEARCH》 *
HIROKAZU KAMBARA等: "An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain Tumor", 《CANCER RESEARCH》 *
HUI LIANG等: "PTENa, a PTEN Isoform Translated through Alternative Initiation, Regulates Mitochondrial Function and Energy Metabolism", 《CELL METABOLISM》 *
HUI WANG等: "Relevance and Therapeutic Possibility of PTEN-Long in Renal Cell Carcinoma", 《PLOS ONE》 *
MIAO DING等: "Prostate Cancer-Specific and Potent Antitumor Effect of a DD3-Controlled Oncolytic Virus Harboring the PTEN Gene" *
XIE ZHANG等: "A PTEN translational isoform has PTEN-like activity", 《CHINESE JOURNAL OF CANCER RESEARCH》 *
文博等: "PTEN增强溶瘤腺病毒对前列腺癌细胞的特异性杀伤作用", 《华中科技大学学报（医学版）》 *

Also Published As

Publication number Publication date
AU2017301901A1 (en) 2019-02-21
JP2022163182A (ja) 2022-10-25
CA3032412A1 (en) 2018-02-01
US20230338443A1 (en) 2023-10-26
EP3490574B8 (en) 2024-07-10
JP2024123088A (ja) 2024-09-10
KR102780496B1 (ko) 2025-03-11
WO2018023114A1 (en) 2018-02-01
KR20190035782A (ko) 2019-04-03
JP2019523008A (ja) 2019-08-22
JP7638061B2 (ja) 2025-03-03
BR112019001737A2 (pt) 2019-05-07
EP4403229A2 (en) 2024-07-24
EP3490574B1 (en) 2024-05-22
EP3490574A1 (en) 2019-06-05
AU2017301901B2 (en) 2024-08-29
SG11201900815UA (en) 2019-02-27
EP3490574A4 (en) 2020-03-04
US20200085890A1 (en) 2020-03-19
EP4403229A3 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
KR102780496B1 (ko) 종양용해성 바이러스에 의한 PTEN-Long의 발현
EP3684924B1 (en) Non-integrating dna vectors for the genetic modification of cells
JP7176737B2 (ja) レトロウイルス核酸配列の切除
US10548914B2 (en) Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2018136396A2 (en) Crisprs
US20120027725A1 (en) Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
US20220290177A1 (en) Compositions and methods for excision with single grna
EP3788070A1 (en) Compositions and methods for hemoglobin production
US20200140865A1 (en) An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents
CA3032412C (en) Expression of pten-long with oncolytic viruses
HK40114297A (en) Expression of pten-long with oncolytic viruses
US20190071673A1 (en) CRISPRs WITH IMPROVED SPECIFICITY
HK40004120A (en) Expression of pten-long with ocolytic viruses
HK40004120B (en) Expression of pten-long with ocolytic viruses
BR112019001737B1 (pt) Vírus herpes simplex (hsv) oncolítico recombinante compreendendo um gene pten-long e seu uso para inibição da metástase de um câncer
RU2678003C1 (ru) Рекомбинантный онколитический штамм вируса осповакцины Л-ИВП_oncoQ, содержащий гены, кодирующие гранулоцитарно-макрофагальный колониестимулирующий фактор и полиэпитопный иммуноген, состоящий из эпитопов антигенов, гиперэкспрессирующихся опухолевыми клетками при раке яичников
US9512429B2 (en) Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer
WO2020068643A1 (en) CRISPRs WITH IMPROVED SPECIFICITY
ITMI20011138A1 (it) Vettore e metodi di impiego per l'espressione selettiva di geni in siti di angiogenesi in vivo
RU2678060C1 (ru) Рекомбинантный онколитический штамм вируса осповакцины Л-ИВП_oncoM, содержащий гены, кодирующие гранулоцитарно-макрофагальный колониестимулирующий фактор и полиэпитопный иммуноген, состоящий из эпитопов антигенов, гиперэкспрессирующихся опухолевыми клетками при меланоме
HK40027038B (en) Non-integrating dna vectors for the genetic modification of cells
HK40027038A (en) Non-integrating dna vectors for the genetic modification of cells
HK40000290A (en) Excision of retroviral nucleic acid sequences

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination